MTSR NASDAQ
New York City, NY 10007
US
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Marso Steven | A-Award | 17,000 | — | 2025-11-13 |
| Marso Steven | D-Return | 120,000 | $29.25 | 2025-11-13 |
| BERNS PAUL L | A-Award | 4,031 | — | 2025-11-13 |
| BERNS PAUL L | D-Return | 24,188 | $29.25 | 2025-11-13 |
| BERNS PAUL L | D-Return | 223,430 | $8.18 | 2025-11-13 |